6
Aug
2025
CAR-T Cells Against Solid Tumors: Sabah Oney on The Long Run
Sabah Oney is today’s guest on The Long Run. Sabah is the CEO of Philadelphia and San Francisco-based Dispatch Biotherapeutics. This startup is developing engineered CAR-T cell therapies for solid tumors. The goal is to bring the power of CAR-T cell cures to a wider group of patients, beyond those with blood cancers. Dispatch was founded by some of the... Read More
5
Aug
2025
VIDEO: Phil Sharp and Bill Haney on ‘Cracking the Code’
Science and society have always had an uneasy relationship. Yet there are always people out there seeking to build bridges of understanding. I recently moderated a conversation at MIT with Phil Sharp, the Nobel Prize-winning biologist, and Bill Haney, a filmmaker and biotech entrepreneur with Dragonfly Therapeutics and Skyhawk Therapeutics. They collaborated on a documentary film called “Cracking the Code.”... Read More
31
Jul
2025
GSK Doubles Down on China, Sarepta Rebounds, and Frazier’s $1.3B Fund
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Jul
2025
Sarepta Crashes, Abivax Soars, & Sanofi Buys Another Vaccine Platform
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Jul
2025
Creative Ways to Back Young Scientists: Andy Rachleff and Yung Lie on The Long Run
Yung Lie and Andy Rachleff are today’s guests on The Long Run. Yung is the president and CEO of the Damon Runyon Cancer Research Foundation, based in New York. Andy is the board chair. Andy was one of the founding partners of Benchmark Capital, the prominent Silicon Valley VC firm, and today is the chairman of Wealthfront. This is a... Read More
22
Jul
2025
Avalyn Pharma Gets $100M to Deliver Inhalable Pulmonary Fibrosis Drugs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Jul
2025
Omega Funds, Delivering New Products and Returns, Secures $647M New Fund
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Jul
2025
Merck Bets $10B on COPD, AbbVie Buys In Vivo CAR-T, & FDA Transparency
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Jul
2025
5AM-Founded Renasant Bio Secures $54.5M Seed for ADPKD Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Jul
2025
Personal Health Platforms Are Evolving. Now, Their Ambition Must Deepen.
I spoke recently at one of my favorite local conferences, an inspirational gathering that brings together remarkable health leaders (plus serendipitous invitees like me) to discuss difficult topics with the exceptional candor afforded by Chatham House rules. While much of the focus was on broad health policy issues, the proceedings were enlivened by presentations from early-stage biopharma and healthcare investors... Read More
1
Jul
2025
A Two-Pronged Attack on Cancer: Claire Mazumdar on The Long Run
Claire Mazumdar is today’s guest on The Long Run. She is the founding CEO of Boston-based Bicara Therapeutics. Bicara is developing a bifunctional antibody for head and neck cancer. It’s called ficerafusp alfa, and it’s designed to bind with a couple of well-known biological targets, EGFR and TGF-beta. The idea is to block a well-known cancer driver in EGFR, while... Read More
25
Jun
2025
AI Drug Discovery: A Revolution for the Underdogs
AI won’t revolutionize drug discovery for Big Pharma. They don’t need it. Pharma has been making remarkable biologic molecules for decades. Not just simple blockers, but a dizzying array of sophisticated therapeutics. Bispecific and multispecific antibodies. T cell engagers. “Masked” molecules that activate specifically in the tumor microenvironment. ATP- and pH-controlled antibodies. Binders to integral membrane proteins like GPCRs and... Read More
25
Jun
2025
The Unsung Community Heroes Who Make Biotech Thrive
Every thriving biotech hub can trace its origins to one or two outstanding scientific institutions. But every thriving region can also trace some of its success back to community leaders. These are people who attend boring night meetings. They aren’t household names. They’re fine with that. These people were especially common in America after World War II. They laid down... Read More
18
Jun
2025
Actio Bio, Running Fast and Lean, Pockets $66M for Precision Neuro Drug R&D
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Jun
2025
From Optimization to Agency: Reframing the Future of Personal Health
While medical advances have afforded us the luxury of longer lives, we now spend many of our later years coping with the ravages of chronic illnesses of aging — cardiovascular disease, type 2 diabetes, neurodegenerative conditions like Alzheimer’s, and cancer. Many of these conditions seem linked to long-term exposure to low grade systemic inflammation, a pathological process known as “inflammaging.” ... Read More
12
Jun
2025
Avidity Advances in FSHD, Insmed Passes PAH Test, Merck Delivers with Oral PCSK9
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Jun
2025
Finding Therapies in Long Non-Coding RNA: John Rinn on The Long Run
John Rinn is today’s guest on The Long Run. John is the Leslie Orgel and Marvin Caruthers professor of RNA science at the University of Colorado in Boulder. His research is focused on long non-coding RNAs. This is the vast expanse of the genome that doesn’t contain genes with code for making proteins. Researchers once dismissed this area of the... Read More
5
Jun
2025
Sanofi Buys Blueprint, BMS Antes for BioNTech Bispecific, & Kymera Degrader Delivers
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Jun
2025
Request an Invitation to the Timmerman Traverse
Timmerman Traverse is looking for a few good men and women. Opportunities are here for people who are physically fit, enjoy nature, thrive in community, and who want to roll up the sleeves for worthy causes — including cancer research, sickle cell disease and fighting poverty. Here’s how to get involved. Timmerman Traverse for Life Science Cares This 2-day expedition... Read More
3
Jun
2025
NEJM Study Linking Exercise, Cancer Recovery Raises Two Concerns: What If It’s Wrong? What If It’s Right?
This week featured a rare crossing of the streams, as the buttoned-down world of cancer research met the buzzy world of exercise and wellness. One result: a randomized controlled study of exercise in 889 cancer patients published in the New England Journal of Medicine (NEJM), and accompanied by a torrent of enthusiastic coverage in the popular press. Another: the publication... Read More